Further studies have shown that ovarian cancer cells that express high LPA1 levels are more resistant to cisplatin-induced apoptosis [65], while LPA3 expression in hepatocarcinoma and breast cancer cells favors cell survival under cisplatin and doxorubicin treatments [66]. This evidence concerns the gene LPAR3 and breast cancer.